NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Aura Biosciences Announces Pricing of Public Offering of Common Stock<
06 Nov 2023

Aura Biosciences Announces Pricing of Public Offering of Common Stock

The gross proceeds from the offering to Aura are expected to be $99.0 million
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma<
06 Nov 2023

Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma

Positive Clinical Efficacy Updates of Bel-sar for Early-Stage Choroidal Melanoma from the Ongoing Phase 2 Clinical Trial

Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting<
02 Nov 2023

Mineralys Therapeutics Presents New Post-Hoc Analysis from Target-HTN Phase 2 Trial of Lorundrostat in Late-Breaking Poster Session at ASN Kidney Week 2023 Meeting

Target-HTN trial results support the transition to late-stage development of lorundrostat as a treatment for uncontrolled and resistant hypertension.

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023<
31 Oct 2023

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023

Presented at the upcoming American Academy of Ophthalmology (AAO) 2023 Annual Meeting being held November 3-6, 2023, in San Francisco.
NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease<
17 Oct 2023

NorthSea Therapeutics Receives FDA Rare Pediatric Disease Designation for SEFA-6179 for the Treatment of Intestinal Failure-Associated Liver Disease

RPD designation underscores critical need for novel therapies to address IFALD
SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease<
17 Oct 2023

SpliceBio Enters Collaboration with Spark Therapeutics to Develop a Gene Therapy Targeting an Inherited Retinal Disease

SpliceBio is eligible to receive upfront, opt-in and milestone payments up to $216 million plus royalties
Cytoki Pharma Presents Preclinical Data Demonstrating Weight Reduction and Improved Glucose Control with Lipidated IL-22 at ObesityWeek 2023<
16 Oct 2023

Cytoki Pharma Presents Preclinical Data Demonstrating Weight Reduction and Improved Glucose Control with Lipidated IL-22 at ObesityWeek 2023

Lipidated IL-22 induced dose-dependent reductions in body weight and blood glucose and improvement
VarmX Promotes CSO Dr. Jeffrey Lawson to New CEO and Moves to New State-of-the-Art Facility<
12 Oct 2023

VarmX Promotes CSO Dr. Jeffrey Lawson to New CEO and Moves to New State-of-the-Art Facility

Dr. Jeffrey Lawson will assume the role of CEO, succeeding Dr. Jan Öhrström who will continue as Chairman.
Anaconda Biomed Announces Additional Granted Patents for its Innovative Thrombectomy Device for Ischemic Stroke Treatment<
12 Oct 2023

Anaconda Biomed Announces Additional Granted Patents for its Innovative Thrombectomy Device for Ischemic Stroke Treatment

The newly granted patents join a list of 17 issued patents for Anaconda Biomed.
AM-Pharma announces positive clinical data from phase 1b study evaluating ilofotase alfa in hypophosphatasia<
11 Oct 2023

AM-Pharma announces positive clinical data from phase 1b study evaluating ilofotase alfa in hypophosphatasia

Ilofotase alfa demonstrates pharmacologically relevant effect on disease specific biomarkers

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.